TODAY”S DATA POINT: In the July 8-10 poll of 1,988 registered voters the pharma industry was the subject of intense ire. Three in 4 voters say they have little or no confidence in drug companies to reduce costs; over half say they don’t trust pharmaceutical companies at all.
Continue reading
KEY THOUGHT: While offering all U.S. citizens free health care using a single-payer system sounds attractive as a political talking point, actually implementing Medicare for All would require a complex restructuring of a multi-trillion dollar industry and cost trillions of dollars. Rather than make promises that don’t make sense politicians should strengthen the ACA and fix its shortfalls.
Continue reading
KEY TAKEAWAY: A survey by the Decision Resource Group reveals that only 34% of physicians feel that pharmaceutical websites are trustworthy. Even fewer (barely a quarter of the 2,784 doctors surveyed) see pharma websites as credible sources for professional information.
Continue reading
KEY TAKEAWAY: The results of an exit survey on two top pharma websites had terrible news for the marketing team. Less than 10% of visitors to the site were going to ask their doctor for/about the medication, and the vast majority (84%) said the website failed to answer their questions about the drug or health condition.
Continue reading
KEY TAKEAWAY: The public sees profits made by pharmaceutical companies as a major factor contributing to the price of prescription drugs. Majorities of the public trust pharmaceutical companies (either “a lot” or “somewhat”) to be good stewards in terms of developing new effective drugs (71 percent), and offering reliable information to consumers about drug safety and side effects (65 percent) as well as drug efficacy (61 percent).
Continue reading
KEY TAKEAWAY: As it appears that the criticism of drug prices from politicians and the President has quieted down, companies are more aggressively and broadly pursuing drug price increases again.
Continue reading
KEY TAKEAWAY: Trump’s threat to issue an executive order on drug pricing, if issued, will be overturned as “unconstitutional”. There are no quick fixes to rein on excessive healthcare costs. They can only be addressed through a thorough bipartisan review of the way our healthcare system function.
Continue reading